The rate of cancer treatment-related cardiac events was 14.9% in patients who received osimertinib and 4.4% in patients who received other EGFR tyrosine kinase inhibitors. Patients with EGFR-mutant ...

The rate of cancer treatment-related cardiac events was 14.9% in patients who received osimertinib and 4.4% in patients who received other EGFR tyrosine kinase inhibitors. Patients with EGFR ...

PFS2 had an HR of 0.75 [95% CI, 0.58-0.98; P = .03], so there's still a major difference between amivantamab [Rybrevant] and lazertinib [Lazcluze] vs osimertinib [Tagrisso], with 72% PFS2 free at 2 ...

Results from the Phase III MARIPOSA trial demonstrated the combination of Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) significantly improves overall survival compared to the current ...

Strategies for managing cardiotoxicity in patients on osimertinib are discussed, focusing on monitoring adverse events and balancing symptom management with maintaining treatment efficacy. News Latest ...